OSI Pharmaceuticals, Inc.
|OSI Pharmaceuticals, Inc. Patent applications|
|Patent application number||Title||Published|
|20110136764||AMINO PYRIMIDINE ANTICANCER COMPOUNDS - Compounds of Formula 1, as shown below and defined herein:||06-09-2011|
|20110015197||mTOR INHIBITOR SALT FORMS - Salt forms of mTOR inhibitors of the Formula (I):||01-20-2011|
|20100286155||ADRENOCORTICAL CARCINOMA TREATMENT - A method of treating adrenocortical carcinoma with OSI-906.||11-11-2010|
|20090286768||SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES - Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention.||11-19-2009|
|20080300249||Isothiazole Derivatives Useful as Anticancer Agents - The present invention relates to compounds of the formula 1||12-04-2008|
|20080261943||PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE - The subject invention provides compounds having the structure:||10-23-2008|
|20080206257||Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor - The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.||08-28-2008|
Patent applications by OSI Pharmaceuticals, Inc.